16α,17α,21-trihydroxy-19-norpregn-4-ene-3,20-dione | 148022-19-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 16α,17α,21-trihydroxy-19-norpregn-4-ene-3,20-dione
• 英文别名: 16α,17α,21-trihydroxy-19-norprogesterone；progestin-16α,17α,21-triol；(8R,9S,10R,13S,14S,16R,17S)-16,17-dihydroxy-17-(2-hydroxyacetyl)-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
• CAS: 148022-19-9
• 化学式: C₂₀H₂₈O₅
• 分子量: 348.439
• InChiKey: CHOXXJSPMQDZKC-RIACROSXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  16α,17α,21-trihydroxy-19-norpregn-4-ene-3,20-dione 在 2,6-二甲基吡啶 、 高氯酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.25h， 生成 16α,17α-<(R)-(1'-α-furylethylidene)dioxy>-21-<<(trifluoromethyl)sulfonyl>oxy>-19-norpregn-4-ene-3,20-dione
  参考文献：
  名称：

  Fluorine-18-labeled progestin 16.alpha.,17.alpha.-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity

  摘要：

  We describe the synthesis and tissue biodistribution of two 21-[fluoro-F-18]progestin 16 alpha,17 alpha-furanyl ketals, potential agents for imaging progesterone receptor (PR)-positive breast tumors in humans, using positron emission tomography. 21-Fluoro-16 alpha,17 alpha-[(R)-(1'-alpha-furyl-methylidene)dioxy]-19-norpregn-4-ene-3,20-dione (endo-10a) and 21-fluoro-16 alpha,17 alpha-[(R)-(1'-alpha-furylethylidene) dioxy]-19-norpregn-4-ene-3,20-dione (endo-10b) were chosen for radiochemical synthesis from a series of seven novel progestin 16 alpha,17 alpha-(furanyldioxolanes) on the basis of their high relative binding affinity to PR (190% and 173%, respectively, relative to R5020 = 100%), their low nonspecific binding (NSB) (log P-o/w = 3.87 and 4.13, respectively), and their resulting high binding selectivity indices (BSI; i.e., the ratio of their PR binding affinity to nonspecific binding). Radiochemical synthesis of these two species in high radiochemical purity and at high effective specific activity was accomplished by treatment of the corresponding diastereomerically pure 21-trifluoromethanesulfonates with fluorine-18 anion. In tissue biodistribution studies in estrogen-primed immature female Sprague-Dawley rats, both [F-18]-endo-10a and [F-18]endo-10b demonstrated high PR-selective uptake in the principal target tissues, the uterus and the ovaries, and relatively low uptake in fat and bone. The metabolism at the 21-position in these progestins (as monitored by in vivo defluorination) appears to be less than that in other 21-fluoroprogestins; this may reflect steric inhibition of metabolism at this site due to the bulk of the furan-substituted dioxolane ring at the 16 alpha,17 alpha-position. Comparison with other fluorine-18-labeled progestins shows that the PR-specific uptake in uterine tissue correlates with the BSI of the ligand and that the fat uptake correlates with the NSB of the ligand at high levels of statistical significance. These two dioxolanes may prove to be useful as breast tumor-imaging agents in humans.

  DOI：

  10.1021/jm00002a014
• 作为产物：
  描述：

  炔诺酮醋酸酯 在 potassium tetrabromopalladate 四氧化锇 、 水 、 氧气 、 potassium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 吡啶 、 甲醇 、 乙二醇二甲醚 、 水 、 乙酸乙酯 为溶剂， 反应 3.25h， 生成 16α,17α,21-trihydroxy-19-norpregn-4-ene-3,20-dione
  参考文献：
  名称：

  制备21-氟孕激素-16α，17α-二氧戊环的有效途径，这是一种用于孕酮受体PET成像的高亲和力配体。

  摘要：

  探索了两种不同的合成路线来合成氟呋喃基正孕酮（FFNP）1，这是孕酮受体（PgR）的高亲和力配体，正在开发为PgR阳性乳腺癌的PET成像剂。两种方法都通过一个关键中间体三醇5进行。第一种方法是从酮缩酮2开始，使用二恶烯基作为合成子在酮醇4中安装皮质类固醇侧链。第二种方法是从乙酸炔丙酯12b开始。 ，涉及应用两步法，Pd（II）催化的氧化重排，然后是碱催化的中间不饱和乙酸酯13b的乙酸重排，以在酮乙酸酯14b中生成必需的皮质类固醇侧链。通过用高锰酸钾有效的二羟基化，用三氟甲磺酸scan的呋喃缩醛化，以及甲磺酸化和氟化反应，将该中间体进一步精制为最终产物1。对于关键中间体三醇5的合成，钯催化的路线比二恶英方法有效得多，特别是三氟甲磺酸scan催化的缩醛化特别是导致了呋喃缩醛醇16a的总产率的显着提高。该途径大大改善了最终孕激素靶标FFNP 1的总产量。尤其是三氟甲磺酸催化的缩醛化导致了呋喃缩醛

  DOI：

  10.1021/jo020190r

文献信息

• Fluorine-18 labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors
  作者：Monica J. Kochanny、Henry F. VanBrocklin、Philip R. Kym、Kathryn E. Carlson、James P. O'Neil、Thomas A. Bonasera、Michael J. Welch、John A. Katzenellenbogen

  DOI：10.1021/jm00061a002

  日期：1993.4

  fluorine-substituted progestins as potential imaging agents for progesterone-receptor-positive human breast tumors. The steroids are 16 alpha, 17 alpha-fluoroacetophenone ketals of 16 alpha, 17 alpha-dihydroxyprogesterone and 16 alpha, 17 alpha, 21-trihydroxy-19-norprogesterone. Synthesis of the latter compound in seven steps from 19-norandrost-4-ene-3,17-dione is reported. Both compounds demonstrate high affinity

  我们已经研究了两种新的氟取代孕激素作为孕激素受体阳性人类乳腺肿瘤的潜在显像剂。类固醇是16α，17α-二羟基孕酮和16α，17α，21-三羟基-19-正孕酮的16α，17α-氟苯乙酮缩酮。据报道，后者的化合物由19-norandrost-4-ene-3,17-dione分七个步骤合成。两种化合物均对孕酮受体（PgR）表现出高度亲和力（相对于R5020 = 100，分别为52.5和240％）。该合成物适合于用4'-[18F]-氟苯乙酮进行18F-标记，所述4'-[18F]-氟苯乙酮是通过用K18F / Kryptofix亲核取代由4'-硝基苯乙酮制备的。需要使用痕量的酮对反应条件进行相当大的调节以实现缩酮化。在雌激素引发的未成年雌性大鼠的组织分布研究中，两种缩酮均显示选择性的子宫摄取，这是通过共注射饱和剂量的未标记孕激素ORG 2058来阻止的。此外，放射性标记物的代谢稳定性表现为低放射性水
• Bromine- and Iodine-Substituted 16α,17α-Dioxolane Progestins for Breast Tumor Imaging and Radiotherapy:  Synthesis and Receptor Binding Affinity
  作者：Dong Zhou、Kathryn E. Carlson、John A. Katzenellenbogen、Michael J. Welch

  DOI：10.1021/jm060348q

  日期：2006.7.1

  Progesterone receptors (PRs) are present in many breast tumors, and their levels are increased by certain endocrine therapies. We describe the synthesis and PR binding affinities of a series of bromine- and iodine-substituted 16 alpha, 17 alpha-dioxolane progestins, some of which, when appropriately radiolabeled, are potential agents for diagnostic imaging of PR-positive breast tumors using positron emission tomography (PET) and for radiotherapy. These compounds were synthesized from halogenated furanyl, phenyl, and thiophenyl aldehydes and a progestin 16 alpha, 17 alpha, 21-triol (5) in the presence of HClO4 or Sc(OTf)(3) in high yields under optimized conditions. A new reagent, perfluoro-1-butanesulfonyl fluoride (PBSF), was used to convert the C-21 OH to F in high yields. The relative binding affinities (RBAs) of the most promising compounds for the PR (RBA of R5020 = 100) were 16 alpha, 17 alpha-[(R)- 1'-R-(5-bromofurylmethylidene)dioxyl]-21-hydroxy-19-norpregn-4-ene-3,20-dione (endo-6; RBA = 65 and moderate lipophilicity), 21-fluoro-16 alpha, 17 alpha-[(R)-1'-alpha-(5-iodofurylmethylidene)dioxyl]-19-norpregn-4-ene-3,20-dione (endo-14; RBA) 40) and 21-fluoro-16 alpha, 17 alpha-[(S)-1'-beta-(4-iodophenylmethylidene)dioxyl]-19-norpregn-4-ene-3,20-dione (exo-16; RBA = 34).